Insider Trading activities of Kite Pharma, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kite Pharma, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kite Pharma, Inc. since year 2005. Table 2 shows the detailed insider transactions of Kite Pharma, Inc. since 2005. The reporting company's ticker symbol is KITE. The reporting company's CIK number is 1510580.
The total value of stock buying since 2005 is $5,803,660.
The total value of stock sales since 2005 is $197,656,377.
The total value of stock option exercises since 2005 is $15,164,987.


 1   2 
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Kite Pharma, Inc. (KITE).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-09 0 $0 56,335 $10,121,367 0 $0
2017-08 0 $0 119,200 $14,014,283 110,200 $5,062,899
2017-07 0 $0 51,649 $5,524,103 51,649 $1,492,619
2017-06 0 $0 97,850 $8,960,339 24,900 $570,244
2017-05 81,682 $5,667,660 22,400 $1,849,088 22,400 $267,160
2017-04 0 $0 280,857 $23,206,120 22,400 $156,360
2017-03 0 $0 166,711 $13,126,910 190,400 $815,279
2017-02 0 $0 59,400 $3,907,762 59,400 $2,546,488
2017-01 0 $0 21,500 $1,081,850 21,500 $37,335
2016-12 0 $0 18,100 $920,988 4,500 $31,005
2016-11 0 $0 21,500 $1,093,670 21,500 $37,335
2016-10 0 $0 1,500 $82,672 1,500 $10,335
2016-09 0 $0 11,500 $628,862 11,500 $23,835
2016-08 0 $0 47,400 $2,834,516 47,400 $1,870,172
2016-07 0 $0 11,500 $584,357 11,500 $23,835
2016-06 0 $0 35,500 $1,904,466 21,500 $37,335
2016-05 0 $0 1,500 $75,000 1,500 $10,335
2016-04 0 $0 10,000 $500,000 10,000 $13,500
2016-03 0 $0 36,006 $1,705,365 36,006 $162,263
2016-02 0 $0 48,217 $2,562,997 48,217 $94,035
2016-01 0 $0 41,812 $2,343,163 41,812 $143,663
2015-12 0 $0 43,712 $2,901,293 43,712 $146,228
2015-11 0 $0 92,212 $7,276,085 92,212 $424,993
2015-10 0 $0 51,412 $3,167,659 51,412 $199,281
2015-09 0 $0 51,412 $3,043,788 51,412 $199,280
2015-08 0 $0 51,412 $3,255,999 51,412 $199,281
2015-07 0 $0 67,434 $4,643,605 67,434 $341,075
2015-06 0 $0 1,023,428 $61,678,282 53,892 $150,935
2015-05 0 $0 46,192 $2,353,692 46,192 $97,882
2015-04 0 $0 10,000 $597,620 0 $0
2015-03 0 $0 193,730 $11,710,476 0 $0
2014-06 8,000 $136,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Kite Pharma, Inc. insiders (KITE)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-09-25 Jenkinson Paul L (Chief Financial Officer) Sale 948 179.66 170,321
2017-09-25 Moore Timothy L. (EVP, Technical Operations) Sale 4,228 179.66 759,619
2017-09-25 Tomasello Shawn (Chief Commercial Officer) Sale 4,203 179.66 755,127
2017-09-25 Chang David D (EVP, R&D, Chief Medical Off.) Sale 7,927 179.66 1,424,196
2017-09-25 Wiezorek Jeffrey (SVP Clinical Development) Sale 5,283 179.66 949,164
2017-09-25 Kim Helen Susan (EVP, Business Development) Sale 3,171 179.66 569,714
2017-09-25 Belldegrun Arie (Chairman, President and CEO) Sale 26,347 179.66 4,733,607
2017-09-25 Butitta Cynthia M (Chief Operating Officer) Sale 4,228 179.66 759,619
2017-08-10 Kim Helen Susan (EVP, Business Development) Sale 6,251 120.09 750,682
2017-08-10 Kim Helen Susan (EVP, Business Development) Option Ex 6,251 52.66 329,208
2017-08-10 Butitta Cynthia M (Chief Operating Officer) Sale 15,000 120.78 1,811,625
2017-08-10 Butitta Cynthia M (Chief Operating Officer) Option Ex 15,000 1.35 20,250
2017-08-08 Kim Helen Susan (EVP, Business Development) Sale 79,949 118.77 9,495,382
2017-08-08 Kim Helen Susan (EVP, Business Development) Option Ex 79,949 53.90 4,309,251
2017-08-03 Moore Timothy L. (EVP, Technical Operations) Sale 6,000 110.08 660,450
2017-08-03 Moore Timothy L. (EVP, Technical Operations) Option Ex 6,000 44.91 269,460
2017-08-01 Moore Timothy L. (EVP, Technical Operations) Sale 12,000 108.01 1,296,144
2017-08-01 Moore Timothy L. (EVP, Technical Operations) Option Ex 3,000 44.91 134,730
2017-07-31 Kim Helen Susan (EVP, Business Development) Sale 26,649 110.16 2,935,653
2017-07-31 Kim Helen Susan (EVP, Business Development) Option Ex 26,649 52.66 1,403,469
2017-07-10 Butitta Cynthia M (Chief Operating Officer) Sale 15,000 102.89 1,543,350
2017-07-10 Butitta Cynthia M (Chief Operating Officer) Option Ex 15,000 1.35 20,250
2017-07-03 Wiezorek Jeffrey (SVP Clinical Development) Sale 10,000 104.51 1,045,100
2017-07-03 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 10,000 6.89 68,900
2017-06-26 Witte Owen N. (Director) Sale 12,500 100.60 1,257,500
2017-06-23 Witte Owen N. (Director) Sale 12,500 100.00 1,250,000
2017-06-23 Witte Owen N. (Director) Option Ex 12,500 34.66 433,312
2017-06-23 Butitta Cynthia M (Chief Operating Officer) Sale 5,000 100.86 504,325
2017-06-16 Champsi Farah (Director) Sale 5,450 88.11 480,199
2017-06-14 Ruchefsky Steven B (Director) Sale 20,000 89.48 1,789,580
2017-06-14 Champsi Farah (Director) Sale 15,000 90.40 1,356,000
2017-06-09 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 88.16 881,600
2017-06-09 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2017-06-08 Doumani Roy (Director) Sale 5,000 84.53 422,635
2017-06-07 Doumani Roy (Director) Sale 10,000 84.46 844,620
2017-06-01 Kim Helen Susan (EVP, Business Development) Sale 2,400 72.45 173,880
2017-06-01 Kim Helen Susan (EVP, Business Development) Option Ex 2,400 51.43 123,432
2017-05-10 Jenkinson Paul L (Chief Financial Officer) Buy 3,450 72.58 250,401
2017-05-09 Nussbaum Ran (Director) Buy 9,832 69.11 679,519
2017-05-09 Ruchefsky Steven B (Director) Buy 1,400 69.50 97,300
2017-05-09 Belldegrun Arie (Chairman, President and CEO) Buy 17,000 68.57 1,165,690
2017-05-09 Bonderman David (Director) Buy 50,000 69.50 3,474,750
2017-05-01 Chang David D (EVP, R&D, Chief Medical Off.) Sale 20,000 82.60 1,652,000
2017-05-01 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 20,000 6.89 137,800
2017-05-01 Kim Helen Susan (EVP, Business Development) Sale 2,400 82.12 197,088
2017-05-01 Kim Helen Susan (EVP, Business Development) Option Ex 2,400 53.90 129,360
2017-04-28 Champsi Farah (Director) Sale 2,617 82.59 216,138
2017-04-27 Champsi Farah (Director) Sale 16,551 82.77 1,369,926
2017-04-26 Champsi Farah (Director) Sale 51,312 82.89 4,253,251
2017-04-25 Butitta Cynthia M (Chief Operating Officer) Sale 15,000 81.97 1,229,505
2017-04-25 Butitta Cynthia M (Chief Operating Officer) Option Ex 15,000 1.35 20,250
2017-04-25 Champsi Farah (Director) Sale 46,783 82.92 3,879,480
2017-04-24 Champsi Farah (Director) Sale 25,818 82.34 2,125,854
2017-04-17 Champsi Farah (Director) Sale 43,101 82.77 3,567,469
2017-04-13 Champsi Farah (Director) Sale 72,275 82.39 5,954,737
2017-04-03 Kim Helen Susan (EVP, Business Development) Sale 2,400 81.80 196,320
2017-04-03 Kim Helen Susan (EVP, Business Development) Option Ex 2,400 53.90 129,360
2017-04-03 Butitta Cynthia M (Chief Operating Officer) Sale 5,000 82.69 413,440
2017-04-03 Butitta Cynthia M (Chief Operating Officer) Option Ex 5,000 1.35 6,750
2017-03-27 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 77.45 774,550
2017-03-27 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2017-03-15 Moore Timothy L. (EVP, Technical Operations) Sale 7,511 83.31 625,741
2017-03-09 Butitta Cynthia M (Chief Operating Officer) Sale 21,118 80.83 1,707,073
2017-03-09 Butitta Cynthia M (Chief Operating Officer) Option Ex 21,118 1.35 28,509
2017-03-01 Chang David D (EVP, R&D, Chief Medical Off.) Sale 60,000 79.41 4,764,600
2017-03-01 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 60,000 6.89 413,400
2017-03-01 Wiezorek Jeffrey (SVP Clinical Development) Sale 18,000 74.89 1,348,020
2017-03-01 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 18,000 6.89 124,020
2017-03-01 Kim Helen Susan (EVP, Business Development) Sale 2,400 74.27 178,248
2017-03-01 Kim Helen Susan (EVP, Business Development) Option Ex 2,400 53.90 129,360
2017-03-01 Doumani Roy (Director) Sale 18,800 75.36 1,416,674
2017-03-01 Doumani Roy (Director) Option Ex 50,000 1.35 67,500
2017-03-01 Butitta Cynthia M (Chief Operating Officer) Sale 28,882 80.05 2,312,004
2017-03-01 Butitta Cynthia M (Chief Operating Officer) Option Ex 28,882 1.35 38,990
2017-02-28 Kim Helen Susan (EVP, Business Development) Sale 47,900 68.49 3,280,623
2017-02-28 Kim Helen Susan (EVP, Business Development) Option Ex 47,900 52.66 2,522,653
2017-02-27 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 55.03 550,320
2017-02-27 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2017-02-01 Wiezorek Jeffrey (SVP Clinical Development) Sale 1,500 51.21 76,819
2017-02-01 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 1,500 6.89 10,335
2017-01-31 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 50.56 505,560
2017-01-31 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2017-01-06 Wiezorek Jeffrey (SVP Clinical Development) Sale 1,500 50.00 75,000
2017-01-06 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 1,500 6.89 10,335
2017-01-06 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 50.13 501,290
2017-01-06 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2016-12-20 Tomasello Shawn (Chief Commercial Officer) Sale 4,901 50.86 249,264
2016-12-20 Chang David D (EVP, R&D, Chief Medical Off.) Sale 1,788 50.86 90,937
2016-12-20 Kim Helen Susan (EVP, Business Development) Sale 936 50.86 47,604
2016-12-20 Belldegrun Arie (Chairman, President and CEO) Sale 3,493 50.86 177,653
2016-12-20 Butitta Cynthia M (Chief Operating Officer) Sale 2,482 50.86 126,234
2016-12-01 Wiezorek Jeffrey (SVP Clinical Development) Sale 3,000 50.95 152,864
2016-12-01 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 3,000 6.89 20,670
2016-11-25 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 50.90 508,950
2016-11-25 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2016-11-10 Wiezorek Jeffrey (SVP Clinical Development) Sale 1,500 50.18 75,270
2016-11-10 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 1,500 6.89 10,335
2016-11-10 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 50.95 509,450
2016-11-10 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2016-10-03 Wiezorek Jeffrey (SVP Clinical Development) Sale 1,500 55.12 82,672
2016-10-03 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 1,500 6.89 10,335
2016-09-26 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 54.13 541,300
2016-09-26 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2016-09-01 Wiezorek Jeffrey (SVP Clinical Development) Sale 1,500 58.38 87,562
2016-09-01 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 1,500 6.89 10,335
2016-08-25 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 58.52 585,250
2016-08-25 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2016-08-15 Kim Helen Susan (EVP, Business Development) Sale 2,400 63.01 151,228
2016-08-15 Kim Helen Susan (EVP, Business Development) Option Ex 2,400 51.43 123,432
2016-08-12 Kim Helen Susan (EVP, Business Development) Sale 33,500 60.08 2,012,613
2016-08-12 Kim Helen Susan (EVP, Business Development) Option Ex 33,500 51.43 1,722,905
2016-08-01 Wiezorek Jeffrey (SVP Clinical Development) Sale 1,500 56.95 85,425
2016-08-01 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 1,500 6.89 10,335
2016-07-25 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 50.94 509,350
2016-07-25 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2016-07-01 Wiezorek Jeffrey (SVP Clinical Development) Sale 1,500 50.01 75,007
2016-07-01 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 1,500 6.89 10,335
2016-06-27 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 50.15 501,480
2016-06-27 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2016-06-23 Butitta Cynthia M (Chief Operating Officer) Sale 10,000 51.27 512,750
2016-06-23 Butitta Cynthia M (Chief Operating Officer) Option Ex 10,000 1.35 13,500
2016-06-06 Doumani Roy (Director) Sale 14,000 58.06 812,896
2016-06-01 Wiezorek Jeffrey (SVP Clinical Development) Sale 1,500 51.56 77,340
2016-06-01 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 1,500 6.89 10,335
2016-05-31 Wiezorek Jeffrey (SVP Clinical Development) Sale 1,500 50.00 75,000
2016-05-31 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 1,500 6.89 10,335
2016-04-04 Butitta Cynthia M (COO and CFO) Sale 10,000 50.00 500,000
2016-04-04 Butitta Cynthia M (COO and CFO) Option Ex 10,000 1.35 13,500
2016-03-15 Wiezorek Jeffrey (SVP Clinical Development) Sale 9,000 46.05 414,432
2016-03-15 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 9,000 6.89 62,010
2016-03-15 Sproule Rizwana F (VP Regulatory Affairs) Sale 8,500 46.58 395,930
2016-03-15 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 8,500 1.35 11,475
2016-03-15 Roberts Margo R (Chief Scientific Officer) Sale 8,506 46.40 394,703
2016-03-15 Roberts Margo R (Chief Scientific Officer) Option Ex 8,506 8.85 75,278
2016-03-01 Butitta Cynthia M (COO and CFO) Sale 10,000 50.03 500,300
2016-03-01 Butitta Cynthia M (COO and CFO) Option Ex 10,000 1.35 13,500
2016-02-17 Sproule Rizwana F (VP Regulatory Affairs) Sale 9,567 45.54 435,681
2016-02-17 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 9,567 1.35 12,915
2016-02-16 Wiezorek Jeffrey (SVP Clinical Development) Sale 9,000 44.23 398,115
2016-02-16 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 9,000 6.89 62,010
2016-02-12 Roberts Margo R (Chief Scientific Officer) Sale 18,750 64.16 1,202,962
2016-02-12 Roberts Margo R (Chief Scientific Officer) Option Ex 18,750 .70 13,125
2016-02-02 Butitta Cynthia M (COO and CFO) Sale 1,900 50.13 95,247
2016-02-02 Butitta Cynthia M (COO and CFO) Option Ex 1,900 1.35 2,565
2016-02-01 Better Marc (VP, Product Sciences) Sale 9,000 47.89 430,992
2016-02-01 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2016-01-27 Butitta Cynthia M (COO and CFO) Sale 8,100 51.95 420,778
2016-01-27 Butitta Cynthia M (COO and CFO) Option Ex 8,100 1.35 10,935
2016-01-19 Sproule Rizwana F (VP Regulatory Affairs) Sale 2,767 56.19 155,486
2016-01-19 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 2,767 1.35 3,735
 1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of KITE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kite Pharma, Inc. (symbol KITE, CIK number 1510580) see the Securities and Exchange Commission (SEC) website.